Literature DB >> 20697295

Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases.

Sara De Iudicibus1, Gabriele Stocco, Stefano Martelossi, Margherita Londero, Egle Ebner, Alessandra Pontillo, Paolo Lionetti, Arrigo Barabino, Fiora Bartoli, Alessandro Ventura, Giuliana Decorti.   

Abstract

BACKGROUND: Glucocorticoids (GCs) are used in moderate-to-severe inflammatory bowel diseases (IBD) but their effect is often unpredictable. AIM: To determine the influence of 4 polymorphisms in the GC receptor [nuclear receptor subfamily 3, group C, member 1 (NR3C1)], interleukin-1β (IL-1β), and NACHT leucine-rich-repeat protein 1 (NALP1) genes, on the clinical response to steroids in pediatric patients with IBD.
METHODS: One hundred fifty-four young IBD patients treated with GCs for at least 30 days and with a minimum follow-up of 1 year were genotyped. The polymorphisms considered are the BclI in the NR3C1 gene, C-511T in IL-1β gene, and Leu155His and rs2670660/C in NALP1 gene. Patients were grouped as responder, dependant, and resistant to GCs. The relation between GC response and the genetic polymorphisms considered was examined using univariate, multivariate, and Classification and Regression Tree (CART) analysis.
RESULTS: Univariate analysis showed that BclI polymorphism was more frequent in responders compared with dependant patients (P=0.03) and with the combined dependant and resistant groups (P=0.02). Moreover, the NALP1 Leu155His polymorphism was less frequent in the GC responsive group compared with resistant (P=0.0059) and nonresponder (P=0.02) groups. Multivariate analysis comparing responders and nonresponders confirmed an association between BclI mutated genotype and steroid response (P=0.030), and between NALP1 Leu155His mutant variant and nonresponders (P=0.033). An association between steroid response and male sex was also observed (P=0.034). In addition, Leu155His mutated genotype was associated with steroid resistance (P=0.034). Two CART analyses supported these findings by showing that BclI and Leu155His polymorphisms had the greatest effect on steroid response (permutation P value=0.046). The second CART analysis also identified age of disease onset and male sex as important variables affecting response.
CONCLUSIONS: These results confirm that genetic and demographic factors may affect the response to GCs in young patients with IBD and strengthen the importance of studying high-order interactions for predicting response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20697295     DOI: 10.1097/MCG.0b013e3181e8ae93

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

Review 1.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 2.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

3.  Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone.

Authors:  Eva Cuzzoni; Sara De Iudicibus; Fiora Bartoli; Alessandro Ventura; Giuliana Decorti
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis.

Authors:  Tere M Williams; Rachel A Leeth; Daniel E Rothschild; Sheryl L Coutermarsh-Ott; Dylan K McDaniel; Alysha E Simmons; Bettina Heid; Thomas E Cecere; Irving C Allen
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

Review 5.  Inflammasomes and intestinal inflammation.

Authors:  N Zmora; M Levy; M Pevsner-Fishcer; E Elinav
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

Review 6.  MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases.

Authors:  Sara De Iudicibus; Marianna Lucafò; Stefano Martelossi; Chiara Pierobon; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  Amelioration of experimental colitis after short-term therapy with glucocorticoid and its relationship to the induction of different regulatory markers.

Authors:  Helioswilton Sales-Campos; Patrícia R de Souza; Paulo J Basso; Viviani Nardini; Angelica Silva; Fernanda Banquieri; Vanessa B F Alves; Javier E L Chica; Auro Nomizo; Cristina R B Cardoso
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

Review 8.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 9.  The Goldilocks Conundrum: NLR Inflammasome Modulation of Gastrointestinal Inflammation during Inflammatory Bowel Disease.

Authors:  Veronica M Ringel-Scaia; Dylan K McDaniel; Irving C Allen
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

10.  NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome.

Authors:  Cecilia B Levandowski; Christina M Mailloux; Tracey M Ferrara; Katherine Gowan; Songtao Ben; Ying Jin; Kimberly K McFann; Paulene J Holland; Pamela R Fain; Charles A Dinarello; Richard A Spritz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.